Here is a question for the pharmacists amongst us. In Perth, Moclobemide, a reversible monoamine oxidase inhibitor, is becoming popular for the treatment of postnatal depression. The drug company mentions that about 1/30 of mother's dose enters breastmilk, and they give the usual comment about benefit outweighing risk. Does anyone know of any study that has been done into this, as I am dubious about using SSRIs on lactating women (eg Prozac, Zoloft etc), but mothers often find the side-effects of the older tricyclic drugs offputting. Comments anyone?? Fiona Coombes (sometimes confused doc and LC) Perth Western Australia